A spotlight on... Volition's U.S. Clinical Product Strategy.
Sharon was appointed as U.S. Head of Quality and Development Process in April 2022.
Bringing over 20 years of experience within the in vitro diagnostic industry to Volition, Sharon was excited to join the company at such a pivotal stage.
What has she been up to since joining Volition? Find out in the video below.
Our priorities
Infrastructure building:
The first priority has been building a quality infrastructure system within the U.S. After opening the new Innovation Hub in March 2022, our team has been working closely with colleagues based in Belgium, to prepare for FDA approval.
Product development:
Volition's Nu.Q® NETs will be used in a range of clinical studies, including a study at The University of Texas MD Anderson Cancer Center, that will evaluate the role of neutrophil extracellular traps (NETs) in cancer patients with sepsis.
Moreover, Volition has appointed Diagnostic Oncology CRO, LLC to undertake development and clinical validation studies for Nu.Q® NETs and Nu.Q® Cancer tests to determine clinical utility in sepsis and cancer.
Stay in touch
To stay up to date with our developments, sign up to our email alerts, and follow Volition on LinkedIn, Twitter, Facebook, or follow our dedicated Volition Veterinary LinkedIn account.